Targeted Oncology

RAD 101 Shows 90% Primary End Point Success in Brain Metastases Trial

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...
InvestorsHub on MSN

Radiopharm reports 90% concordance in interim results for RAD 101 brain metastases trial

Radiopharm Theranostics (NASDAQ:RADX) announced interim findings from its Phase 2b clinical trial evaluating RAD 101, an ...

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint)First five ...

Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building

Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that ...

Algernon Health highlights NovaScan brand for dedicated brain PET scanning centers

Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) on Wednesday announced “NovaScan Neuroimaging Clinics” as the new brand name ...

Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers

Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging ClinicsTM as the new brand name and visual identity for ...
Vietnam Investment Review on MSN

Telix resubmits brain cancer imaging drug application to FDA

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...